CLINICAL STUDY

IGF receptor gene variants in normal adolescents: effect on stature

Alvina R Kansra, Lawrence M Dolan¹, Lisa J Martin¹, Ranjan Deka² and Steven D Chernausek³

Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA, ¹Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio 45229, USA, ²Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, Ohio 45269, USA and ³Department of Pediatrics, University of Oklahoma Health Sciences Center, 1200 North Phillips Avenue, Suite 4500, Oklahoma City, Oklahoma 73104-4600, USA

(Correspondence should be addressed to S D Chernausek; Email: steven-chernausek@ouhsc.edu)

Abstract

Objective: IGF1 is essential for human growth and mediates its effects through the type 1 IGF receptor (IGF1R). Our objective was to determine the frequency of certain previously reported IGF1R gene variants in the normal population and their effect on stature.

Design: A cross-sectional study was conducted in a population of 2500 children enrolled in public school grades 5 through 12 for whom DNA and anthropometric data were available. Subjects were genotyped at five previously reported loci that affect receptor abundance or function.

Methods: The frequency of the following IGF1R variants Arg108Gln, Lys115Asn, Arg59stop, Arg481Gln, and Arg605His was measured by a PCR-based assay. Circulating concentrations of IGF1 or IGF binding protein-3 (IGFBP3) were measured by ELISA in those affected and matched controls.

Results: A scan of 1300 subjects detected none with Arg108Gln, Lys115Asn, or Arg59stop mutations. In contrast, nucleotide changes leading to heterozygosity at codon 605 were identified in nine of 2500 subjects and six of 1800 subjects at codon 481. These individuals were, on average, 4 cm shorter than the others. There were no differences in circulating concentrations of IGF1 or IGFBP3 between those with the gene variants and controls matched for sex, ethnicity, age, and BMI.

Conclusion: Rare IGF1R variants exerting a moderate effect on stature are present in the general population, supporting the importance of IGF1R function in growth control and indicating that variation in height within healthy individuals may be explained, in some cases, by larger effects of a small subset of gene variants.

European Journal of Endocrinology 167 777–781

Introduction

Approximately 80% of the variation in human stature is explained by heritable factors (1). Genome-wide association studies have identified more than 180 common genetic variants that influence stature within a general population, but in aggregate, these account for only 10% of the variation in human height (2). Even though these common variants are related to stature across a wide range of height, there is also evidence that rare genetic variants with larger effects on stature are involved (3).

The type 1 insulin-like growth factor receptor gene (IGF1R) represents a locus where rare genetic variants might exert relatively large effects on stature. Normal abundance and function of the IGF1R is critical for normal growth as evidenced by gene deletion studies in mice (4) and reports of humans with variation in IGF1R number and sequence (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17). Homozygous Igf1r null mice are very small at birth and do not survive, and all affected humans described to date have genetic lesions compatible with partial IGF1R function. These findings imply that the complete lack of IGF1R signaling is incompatible with life and that graded reductions in IGF1R function will significantly attenuate growth.

We previously described two children with severe growth failure due to IGF1R mutations (10). In one of the cases reported, the child was a compound heterozygote for IGF1R mutations that reduced IGF1 binding and signaling. The below-average stature of her parents (height SDS – mother – 1.6, father – 2.8), each of whom carried one mutant allele, led us to postulate that similar variations in IGF1R would be found to exert moderate effects on growth within the normal population. We tested this by assessing the frequency of five specific IGF1R variants in a school-based cohort of adolescents and determining the effect of these variants on stature.
Materials and methods

Study population

Serum, DNA, and anthropometric data were obtained from individuals who participated in a school-based study that began in 2002 and was designed to assess risk, prevalence, and features of metabolic disease in children (18). In total 2501 of the 4273 students in grades 5 through 12 (ages 9.6–20.4 years) from a suburban school system participated in that study. Of those, 1263 (50%) were non-Hispanic White and 1117 (45%) African–American. The rest were Hispanic, Asian, West Indian, or multi-racial. Inclusion and exclusion criteria required each subject to have no known chronic disease and be taking no medication(s) known to affect carbohydrate metabolism. Pregnant females were excluded. The protocol was reviewed and approved by the Institutional Review Board at Cincinnati Children’s Hospital Medical Center with written informed consent obtained from the parent/legal guardian and assent obtained from the subject.

Study protocol

Research subjects were evaluated annually. After a 10-h overnight fast, the following procedures were performed at the student’s school: i) confirmation of the length of the fast and completion of the medical history; ii) height, weight, and documentation of the stage of axillary hair; and iii) venipuncture. Parents and students completed a personal medical history for each participant documenting chronic disease, medication use, and family history of diabetes. Blood samples were maintained on wet ice, processed within 3 h of venipuncture, and stored at −20 °C.

Height and weight were measured using standard procedures and equipment as described previously (19). Pubertal status (prepubertal, pubertal and post-pubertal) was assigned using criteria as described previously (18). For females, prepubertal status was defined as estradiol <11 pg/ml, pubertal was defined as estradiol ≥11 pg/ml without menarche, or duration of menarche <2 years, and postpubertal status was defined as the presence of menses for >2 years. In males, prepubertal status was defined as free testosterone <1.0 pg/ml, pubertal was defined as free testosterone ≥1.0 pg/ml, and axillary hair equal to stage III, and postpubertal status was defined as free testosterone ≥1.0 pg/ml and axillary hair stage III. These cutoffs were derived from an analysis of subjects who had pubertal staging by standard physical examination and their discrimination validated by operator characteristic curve analysis (18). It was anticipated that those classified as postpubertal were at final or near-final height.

Hormone assays

IGF1 and IGF binding protein-3 (IGFBP3) were measured by ELISA using assay kits from Diagnostic Systems Laboratories (Webster, TX, USA) following the manufacturer’s instructions. Intra- and interassay coefficients of variation were <7%. Free testosterone and estradiol were measured by RIA and competitive protein binding assay respectively as previously reported (20).

Statistical analysis

Data were examined for normality before analysis. All data were normally distributed, so no transformations were required. Because puberty is associated with accelerated growth velocity, we restricted the initial analysis to postpubertal measures of stature.

As these students participated in up to five annual study visits, we used mixed models analysis (Proc MIXED, SAS (version 9.1), Cary, NC, USA). Inclusion criteria for the analysis were either African–American or White self-reported race (due to the small number of other racial/ethnic groups) and postpubertal height data. The mixed models analysis accounts for both the intra- and the interindividual variability present in these data, resulting in larger, and more valid, estimates of standard error (21). Next, we evaluated the covariance structure of the data. Variance components,
unstructured, and compound symmetry were examined. Compound symmetry fits the data best, so all models use compound symmetry for the covariance structure.

Because we expected the IGF1R mutations to be rare, we made an a priori decision to combine those harboring any of the mutations for analysis. Individuals were scored on the presence or absence of one or more of the IGF1R variants. Age, race, and sex were included as covariates. We considered significant effects to be present if P ≤ 0.05.

Results

Frequency of genetic variants

A preliminary scan of 1300 subjects who were unrelated but otherwise randomly selected from the 2500 detected none with Arg108Gln, Lys115Asn, or Arg59stop mutations. Given the low frequency, no further testing for these mutations was conducted. In contrast, nucleotide changes leading to heterozygosity at codon 605 (rs45553041) were identified in nine of 2500 subjects, and six of 1800 were heterozygous at IGF1R residue 481 (codon 511, rs33958176). The frequencies of rs33958176 are consistent with those in 2500 subjects, and six of 1800 were heterozygous at IGF1R residue 481 (codon 511, rs33958176). The frequencies of rs33958176 are consistent with those reported in the NCBI SNP database (MAF = 0.001) (http://www.ncbi.nlm.nih.gov/snp) and the NHLBI exome database (MAF = 0.0013) (http://evs.gs.washington.edu/EVS/). SNP rs45553041 does not have a frequency listed in the NCBI SNP database and is not reported in the NHLBI exome database. Demographic, auxological, and hormonal data on those harboring the variants are displayed in Table 1 and shown in comparison with the 1800 controls that were postpubertal. Although there were apparent differences in sex and race distribution between variants and controls, these factors were accounted for in subsequent analyses. Circulating concentrations of testosterone appeared to be increased in those harboring IGF1R variants relative to controls, but the number of male subjects was small (n = 11) and could be due to other factors. Thus, the finding is of uncertain significance at this time. Resource constraints limited the analysis to only 1800 samples for the codon 511 variant; the limitation was arbitrary and there was no difference in gender, proportion of African–American and White participants, or heights from the 2500 subject group.

Effect on stature

After adjusting for age, sex, and race, postpubertal height was reduced in those subjects with the IGF1R variants by 4 ± 2 cm (P = 0.03) in mixed models. Because there were up to 4 yearly measures available for each subject, regression analyses were performed by study year, using mixed models accounting for repeated measures. Regression analysis provided similar effect sizes in all 4 years of data (3.5–5.5 cm reduced height in those with a variant). In fact, there was no change in heights in the postpubertal subjects across those 4 years, irrespective of whether they harbored the variant or not, indicating that the variants reduced final height. Further, analysis of height for age z-scores resulted in similar effects (data not shown). None of the individuals harboring IGF1R variants enrolled before the onset of puberty. Therefore, the effect on prepubertal growth could not be assessed.

Effect on circulating concentrations of IGF1 and IGFBP3

The reduction in stature associated with IGF1R variants suggested that these individuals were relatively IGF resistant. Previous reports indicate that IGF1 and IGFBP3 levels are increased in some individuals with IGF resistance due to IGF1R mutations (7, 8, 10, 11). Therefore, we sought additional evidence for IGF resistance by comparing circulating concentrations of IGF1 and IGFBP3 in the IGF1R variant subjects with controls (Table 2). Each individual harboring an IGF1R variant was matched by age, sex, BMI, and race with three individuals from the study population who had none of the tested variants. All were postpubertal at the time of assessment. There were no differences between the variants and controls in the tabulated measures.

Discussion

Previous reports examining IGF1R variations in humans have either identified a pathogenic mutation in an affected individual with support of functional and
occasional family studies or identified common variants influencing stature via genome-wide association studies. This study differs from those in that we focused on a few specific genetic variations in IGFR1 that plausibly attenuate IGF1 signaling and measured the effect in a normal adolescent population. We find that harboring a single copy of certain IGFR1 variants leads to a substantial (4 cm) decrease in height on average, an observation supported by a recent computational analysis that predicts functional effects of these specific variants (22). This indicates that variation in height within healthy individuals may be explained, in some cases, by larger effects of a small subset of gene variants, rather than the combined small effects of many genes. Though the frequency of such IGFR1 variants reported here is very low, we sought a highly restricted number of specific genetic variants. Thus, it is likely that additional rare variations of IGFR1 also influence height within the normal population.

Our finding that these IGFR1 variants were not associated with changes in circulating concentrations of IGF1 and IGFBP3 is somewhat unexpected. If the IGFR receptor changes we found result in a state of IGF resistance, then one would anticipate a reciprocal increase in GH secretion resulting in higher levels of IGF1 and IGFBP3 in the circulation. We reported this in the case with compound heterozygosity for IGFR1 mutations (10). Because we made our measures in the postpubertal state, it is conceivable that there is a developmental or age-sensitive effect of the variants on circulating IGF1 concentrations that disappears post-puberty. However, increased concentrations of IGF1 and IGFBP3 have not been uniformly observed in other cases of biologically significant IGFR1 mutations, including some with severe short stature (6, 9, 15, 16). The exact reasons for this are unclear but likely reflect the wide variation in serum levels among the general population and the multiple variables influencing circulating IGF1 concentrations.

We selected one of our genetic variants based on the family described by Inagaki et al. (7). Surprisingly, the individuals reported by Inagaki et al. were much more severely affected by the mutation than our cases, with heights from the former being in the −5 to −6 s.d. range. The authors verified that these mutations were biologically significant by demonstrating that cultured cells expressing the mutant IGFR1 showed reduced IGFR1 signaling and proliferation in response to stimulation with IGF1. It is possible that the more severe phenotype reported by Inagaki et al. is explained by additional genetic variations that add to the effect of reduced IGF1 signaling. In support of the latter, there were modest reductions in stature (−1.2 to −2.2 s.d. below average) in the presumably non-affected family members.

The strengths of this study are that we selected IGFR1 variants of proven or plausible biological significance and examined the effect in a representative population of normal adolescents with no other a priori assumptions as to results. A weakness of our study is lack of complete growth measurements, including birth anthropometrics, on all participants and the use of indirect measures to stage puberty. These shortcomings reflect the fact that the original purpose of the study was to examine metabolic state of the population, not growth and puberty. Thus, the height deficit we report could reflect modest growth attenuation throughout life or could be due to differences in the pubertal spurt (timing or magnitude). We could not assess the effects of the variants on prepubertal growth as they had all entered puberty at the time of enrollment. Nonetheless, the effect on stature was clearly evident with an appropriate statistical approach. Furthermore, the possibility that the variants simply influence pubertal timing and not final height is remote because the postpubertal state, as defined, placed the subjects very close to final height (e.g. >2 years post-menarche for females). Measurements of circulating sex steroids were not lower in variants compared with controls, and analysis of consecutive measures of height indicated that growth had ceased in the variants and comparison group.

Another weakness is that we did not survey all known pathogenic IGFR1 variants, including copy number variations. In some cases, this was because of technical limitations as noted previously; in others, the gene variants had not been reported at the time we conducted the study. However, the main purpose was not to determine the frequency and effect size of all known IGFR1 variants but rather to test the hypothesis that rare IGFR1 variants will produce relatively larger effects on stature in the general population. Indeed, this is what we found, providing further support for the critical role of the IGFR1 in the pathway of growth control in humans.

Declaration of interest
S D Chernausek received research funding for this project from Eli Lilly and Company. A R Kansra, L M Dolan, L J Martin, and R Deka have nothing to disclose.

Funding
This work was supported by grants from Eli Lilly and Company, the National Institutes of Health (RO 1 DK59183), and an Institutional
Clinical and Translational Science Award, NIH/NCRR (1UL1RR026314-01). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Acknowledgements
The authors wish to thank Walter Banach for his expertise in performing the hormone assays.

References

Received 28 February 2012
Revised version received 28 August 2012
Accepted 12 September 2012